Patents Assigned to aTyr Pharma, Inc.
  • Therapeutic compositions comprising anti-NRP2 antibodies
    Patent number: 11807687
    Abstract: Provided are affinity matured and humanized antibodies and antigen-binding fragments thereof that specifically bind to human neuropilin-2 (NRP2) polypeptides, including those that modulate binding interactions between human NRP2 and at least one NRP2 ligand, and which thereby modulate subsequent NRP2-mediated downstream signaling events, including related therapeutic compositions and methods for modulating NRP2 activity and treating diseases such as NRP2-associated diseases.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: November 7, 2023
    Assignee: aTyr Pharma, Inc.
    Inventors: Luke Burman, Yeeting Chong, Leslie Ann Greene, David King, Zhiwen Xu, Ryan Andrew Adams
  • Compositions and methods for treating lung inflammation
    Patent number: 11767520
    Abstract: Provided are therapies, including combination therapies, for the treatment of lung inflammation, including interstitial lung diseases (ILDs), which include the use of at least one histidyl-tRNA synthetase (HRS) polypeptide or an expressible polynucleotide that encodes the HRS polypeptide, alone or in combination with at least one immunomodulatory agent.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: September 26, 2023
    Assignee: aTyr Pharma, Inc.
    Inventors: John D. Mendlein, Kathleen Ogilvie
  • Compositions and methods comprising anti-NRP2 antibodies
    Patent number: 11505610
    Abstract: Provided are antibodies and antigen-binding fragments thereof that specifically bind to human neuropilin-2 (NRP2) polypeptides, including those that modulate binding interactions between human NRP2 and at least one NRP2 ligand, for example, human histidyl-tRNA synthetase (HRS), and which thereby modulate subsequent NRP2-mediated downstream signaling events, including related therapeutic compositions and methods for modulating NRP2 activity and treating diseases such as NRP2-associated diseases.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: November 22, 2022
    Assignee: aTyr Pharma, Inc.
    Inventors: Luke Burman, Yee Ting (Esther) Chong, Yanyan Geng, Leslie Nangle Greene, Kristina Hamel, David King, Ann Menefee, Kaitlyn Rauch, Zhiwen Xu, Liting Zhai
  • Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities
    Patent number: 11078299
    Abstract: Isolated histidyl-tRNA synthetase splice variant polynucleotides and polypeptides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: August 3, 2021
    Assignees: aTyr Pharma, Inc., Pangu BioPharma Limited
    Inventors: Jie Zhou, Ching-Fun Lau, Zhiwen Xu, Wing-Sze Lo, Kristi Helen Piehl, Leslie Ann Greene
  • Histidyl-tRNA synthetase-Fc conjugates
    Patent number: 11072787
    Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: July 27, 2021
    Assignee: aTyr Pharma Inc.
    Inventors: Chi-Fang Wu, Darin Lee, Jeffry D. Watkins, Kristi Piehl, Kyle P. Chiang, Marc Thomas, Minh-Ha Do, Ying Buechler, John D. Mendlein
  • Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities
    Patent number: 10941214
    Abstract: Isolated histidyl-tRNA synthetase splice variant polynucleotides and polypeptides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: March 9, 2021
    Assignees: aTyr Pharma, Inc., Paneu BioPharma Limited
    Inventors: Jie Zhou, Ching-Fun Lau, Zhiwen Xu, Wing-Sze Lo, Kristi Helen Piehl, Leslie Ann Greene
  • Histidyl-tRNA synthetase-Fc conjugates
    Patent number: 10711260
    Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: July 14, 2020
    Assignee: aTyr Pharma, Inc.
    Inventors: Chi-Fang Wu, Darin Lee, Jeffry D. Watkins, Kristi Piehl, Kyle P. Chiang, Marc Thomas, Minh-Ha Do, Ying Buechler, John D. Mendlein
  • Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Histidyl-tRNA synthetases
    Patent number: 10669533
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: June 2, 2020
    Assignees: aTyr Pharma, Inc., Pangu BioPharma Limited
    Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain P. Vasserot, Wing-Sze Lo, Jeffry Dean Watkins, Cheryl L. Quinn, John D. Mendlein
  • Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of tryptophanyl tRNA synthetases
    Patent number: 10563191
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: February 18, 2020
    Assignees: aTyr Pharma, Inc., Pangu BioPharma Limited
    Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain P. Vasserot, Wing-Sze Lo, Jeffry D. Watkins, Cheryl L. Quinn, John D. Mendlein
  • Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl-tRNA synthetases
    Patent number: 10563192
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: February 18, 2020
    Assignees: aTyr Pharma, Inc., Pangu BioPharma Limited
    Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain P. Vasserot, Wing-Sze Lo, Jeffry D. Watkins, Cheryl L. Quinn, John D. Mendlein
  • Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities
    Patent number: 10526419
    Abstract: Isolated histidyl-tRNA synthetase splice variant polynucleotides and polypeptides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: January 7, 2020
    Assignees: aTyr Pharma, Inc., Pangu BioPharma Limited
    Inventors: Jie Zhou, Ching-Fun Lau, Zhiwen Xu, Wing-Sze Lo, Kristi Helen Piehl, Leslie Ann Greene
  • Histidyl-tRNA synthetase-Fc conjugates
    Patent number: 10472618
    Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: November 12, 2019
    Assignees: aTyr Pharma, Inc., Pangu Biopharma Limited
    Inventors: Chi-Fang Wu, Darin Lee, Jeffry D. Watkins, Kristi Piehl, Kyle P. Chiang, Marc Thomas, Minh-Ha Do, Ying Buechler, John D. Mendlein
  • Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-tRNA synthetases
    Patent number: 10196628
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: February 5, 2019
    Assignees: aTyr Pharma, Inc., Pangu Biopharma Limited
    Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain P. Vasserot, Wing-Sze Lo, Jeffry D. Watkins, Cheryl L. Quinn, John D. Mendlein
  • Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
    Patent number: 10196629
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: February 5, 2019
    Assignees: aTyr Pharma, Inc., Pangu BioPharma Limited
    Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain P. Vasserot, Wing-Sze Lo, Jeffry D. Watkins, Cheryl L. Quinn, John D. Mendlein
  • Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Valyl-tRNA synthetases
    Patent number: 10189911
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: January 29, 2019
    Assignees: aTyr Pharma, Inc., Pangu Biopharma Limited
    Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain P. Vasserot, Wing-Sze Lo, Jeffry D. Watkins, Cheryl L. Quinn, John D. Mendlein
  • Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases
    Patent number: 10179908
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: January 15, 2019
    Assignees: aTyr Pharma, Inc., Pangu Biopharma Limited
    Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain P. Vasserot, Wing-Sze Lo, Jeffry D. Watkins, Cheryl L. Quinn, John D. Mendlein
  • Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
    Patent number: 10179906
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: January 15, 2019
    Assignees: aTyr Pharma, Inc., Pangu Biopharma Limited
    Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alian P. Vasserot, Wing-Sze Lo, Jeffry D. Watkins, Cheryl L. Quinn, John D. Mendlein
  • Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutamyl-prolyl-tRNA synthetases
    Patent number: 10160814
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: December 25, 2018
    Assignees: aTyr Pharma, Inc., Pangu BigPharma Limited
    Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain P. Vasserot, Wing-Sze Lo, Jeffry D. Watkins, Cheryl L. Quinn, John D. Mendlein
  • Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl-tRNA synthetases
    Patent number: 10150958
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: December 11, 2018
    Assignees: aTyr Pharma, Inc., Pangu Biopharma Limited
    Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain P. Vasserot, Wing-Sze Lo, Jeffry D. Watkins, Cheryl L. Quinn, John D. Mendlein
  • Histidyl-tRNA synthetase-Fc conjugates
    Patent number: 10093915
    Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: October 9, 2018
    Assignee: aTyr Pharma Inc.
    Inventors: Chi-Fang Wu, Darin Lee, Jeffry D. Watkins, Kristi Piehl, Kyle P. Chiang, Marc Thomas, Minh-Ha Do, Ying Buechler, John D. Mendlein